Cutting edge: Transplantation tolerance through enhanced CTLA-4 expression

被引:65
作者
Ariyan, C
Salvalaggio, P
Fecteau, S
Deng, SY
Rogozinski, L
Mandelbrot, D
Sharpe, A
Sayegh, MH
Basadonna, GP
Rothstein, DM
机构
[1] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA
[3] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA
[4] Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01655 USA
[5] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[6] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[7] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
D O I
10.4049/jimmunol.171.11.5673
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Knockout and blocking studies have shown a critical role for CTLA-4 in peripheral tolerance, however, it is unknown whether augmenting CTLA-4 expression actually promotes tolerance. Here we demonstrate a specific and requisite role for CTLA-4 and its up-regulation in tolerance through anti-CD45RB. First, long-term murine islet allograft survival induced by anti-CD45RB is prevented by CTLA44g, which interferes with B7.-CTLA-4 interactions. Second, anti-CD45RB is ineffective in recipients lacking ng LA-4,B7-1, and B7-2. Incontrast, CTLA4-Ig, which targets B17 on allogeneic cells, promotes long-term engraftment in these mice. Moreover, anti-CD45Rb was effective in X-deficient controls expressing CTLA-4. Finally, in wildtype mice, CTLA-4 expression returned to baseline 17 days after receiving anti-CD45RB, and was refractory to further increase. Transplantation and anti-CD45RB therapy at this time could neither augment CTLA-4 nor prolong engraftment, These data demonstrate a specific role for CTLA-4 in anti-CD45RB-mediated tolerance and indicate that CTLA-4 up-regulation can directly promote allograft survival.
引用
收藏
页码:5673 / 5677
页数:5
相关论文
共 23 条
[1]  
Alegre ML, 1996, J IMMUNOL, V157, P4762
[2]   Antibody-mediated targeting of CD45 isoforms: A novel immunotherapeutic strategy [J].
Basadonna, GP ;
Auersvald, L ;
Khuong, CQ ;
Zheng, XX ;
Kashio, N ;
Zekzer, D ;
Minozzo, M ;
Qian, HY ;
Visser, L ;
Diepstra, A ;
Lazarovits, AI ;
Poppema, S ;
Strom, TB ;
Rothstein, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :3821-3826
[3]   CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy [J].
Chambers, CA ;
Kuhns, MS ;
Egen, JG ;
Allison, JP .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :565-594
[4]   Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4 [J].
Chikuma, S ;
Imboden, JB ;
Bluestone, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (01) :129-135
[5]   CTLA-4 up-regulation plays a role in tolerance mediated by CD45 [J].
Fecteau, S ;
Basadonna, GP ;
Freitas, A ;
Ariyan, C ;
Sayegh, MH ;
Rothstein, DM .
NATURE IMMUNOLOGY, 2001, 2 (01) :58-63
[6]   Negative co-receptors on lymphocytes [J].
Greenwald, RJ ;
Latchman, YE ;
Sharpe, AH .
CURRENT OPINION IN IMMUNOLOGY, 2002, 14 (03) :391-396
[7]   Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152) [J].
Griffin, MD ;
Hong, DK ;
Holman, PO ;
Lee, KM ;
Whitters, MJ ;
O'Herrin, SM ;
Fallarino, F ;
Collins, M ;
Segal, DM ;
Gajewski, TF ;
Kranz, DM ;
Bluestone, JA .
JOURNAL OF IMMUNOLOGY, 2000, 164 (09) :4433-4442
[8]   CTLA-4-Ig regulates tryptophan catabolism in vivo [J].
Grohmann, U ;
Orabona, C ;
Fallarino, F ;
Vacca, C ;
Calcinaro, F ;
Falorni, A ;
Candeloro, P ;
Belladonna, ML ;
Bianchi, R ;
Fioretti, MC ;
Puccetti, P .
NATURE IMMUNOLOGY, 2002, 3 (11) :1097-1101
[9]   CD45: A critical regulator of signaling thresholds in immune cells [J].
Hermiston, ML ;
Xu, Z ;
Weiss, A .
ANNUAL REVIEW OF IMMUNOLOGY, 2003, 21 :107-137
[10]   Cutting edge: Targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells [J].
Hwang, KW ;
Sweatt, WB ;
Brown, IE ;
Blank, C ;
Gajewski, TF ;
Bluestone, JA ;
Alegre, ML .
JOURNAL OF IMMUNOLOGY, 2002, 169 (02) :633-637